SCHEMBL10184458

SCHEMBL10184458

C[C@@H](NC(=O)c1cn[nH]c1-c1ccccc1)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.59
EPHB6 O15197 1/20 0.59
ABL1 P00519 1/20 0.59
RAF1 P04049 1/20 0.59
PDGFRB P09619 1/20 0.59
BCR P11274 1/20 0.59
EPHA1 P21709 1/20 0.59
EPHA2 P29317 1/20 0.59
WEE1 P30291 1/20 0.59
TGFBR2 P37173 1/20 0.59
ABL2 P42684 1/20 0.59
FRK P42685 1/20 0.59
MAP2K4 P45985 1/20 0.59
CLK1 P49759 1/20 0.59
LIMK1 P53667 1/20 0.59
EPHB4 P54760 1/20 0.59
DDR1 Q08345 1/20 0.59
MAP3K1 Q13233 1/20 0.59
DYRK1A Q13627 1/20 0.59
MYLK Q15746 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10235536 0.87 ABL1 (0.64) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10233722 0.85 ABL1 (0.62) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL13472918 0.82 ABL1 (0.64) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10235192 0.80 BRAF (0.58) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10235570 0.80 ABL1 (0.66) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10235195 0.80 BRAF (0.66) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10235198 0.80 MAPK14 (0.62) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10235563 0.79 ABL1 (0.76) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10233628 0.79 BRAF (0.59) BRAFEPHB6ABL1RAF1PDGFRB
SCHEMBL10235191 0.79 BRAF (0.59) BRAFEPHB6ABL1RAF1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF BRAF 1/4885EPHB6 1763/4885ABL1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.